文献速递临床试验与 GCP流行病学与生物统计

高频对比低频随访检测对II或III期结直肠癌患者总死亡率及癌特异死亡率的影响:COLOFOL随机临床试验

Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

该非盲随机试验纳入2509例II或III期结直肠癌根治术后患者,比较高频与低频CT和CEA随访检测。高频组5年总死亡率为13.0%,低频组为14.1%,风险差1.1%(95%CI -1.6%至3.8%;癌特异死亡率分别为10.6%和11.4%,风险差0.8%(95%CI -1.7%至3.3%;

要点

  • 高频随访未显著降低II/III期结直肠癌根治术后5年总死亡率。
  • 高频随访未显著降低结直肠癌特异死亡率及复发率。
  • 临床实践中可考虑采用低频CT和CEA随访方案。

核心结论

  • 在II或III期结直肠癌根治术后患者中,高频对比低频CT和CEA随访检测未显著降低5年总死亡率和结直肠癌特异死亡率。

研究设计与样本

  • 非盲随机试验纳入2509例II或III期结直肠癌患者,来自瑞典、丹麦和乌拉圭24个中心,2006年1月至2010年12月入组,随访5年。
  • 高频组(n=1253)在术后6、12、18、24、36个月行胸腹部CT和血清CEA检测,低频组(n=1256)在术后12和36个月检测。

临床怎么用

  • 对于II或III期结直肠癌根治术后患者,高频CT和CEA随访检测未显示生存获益,临床可考虑采用低频随访方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intensive follow-up of patients after curative surgery for colorectal cancer is common in clinical practice, but evidence of a survival benefit is limited. OBJECTIVE: To examine overall mortality, colorectal cancer-specific mortality, and colorectal cancer-specific recurrence rates among patients with stage II or III colorectal cancer who were randomized after curative surgery to 2 alternative schedules for follow-up testing with computed tomography and carcinoembryonic antigen. DESIGN, SETTING, AND PARTICIPANTS: Unblinded randomized trial including 2509 patients with stage II or III colorectal cancer treated at 24 centers in Sweden, Denmark, and Uruguay from January 2006 through December 2010 and followed up for 5 years; follow-up ended on December 31, 2015. INTERVENTIONS: Patients were randomized either to follow-up testing with computed tomography of the thorax and abdomen and serum carcinoembryonic antigen at 6, 12, 18, 24, and 36 months after surgery (high-frequency group; n = 1253 patients) or at 12 and 36 months after surgery (low-frequency group; n = 1256 patients). MAIN OUTCOMES AND MEASURES: The primary outcomes were 5-year overall mortality and colorectal cancer-specific mortality rates. The secondary outcome was the colorectal cancer-specific recurrence rate. Both intention-to-treat and per-protocol analyses were performed. RESULTS: Among 2555 patients who were randomized, 2509 were included in the intention-to-treat analysis (mean age, 63.5 years; 1128 women [45%]) and 2365 (94.3%) completed the trial. The 5-year overall patient mortality rate in the high-frequency group was 13.0% (161/1253) compared with 14.1% (174/1256) in the low-frequency group (risk difference, 1.1% [95% CI, -1.6% to 3.8%]; P = .43). The 5-year colorectal cancer-specific mortality rate in the high-frequency group was 10.6% (128/1248) compared with 11.4% (137/1250) in the low-frequency group (risk difference, 0.8% [95% CI, -1.7% to 3.3%]; P = .52). The colorectal cancer-specific recurrence rate was 21.6% (265/1248) in the high-frequency group compared with 19.4% (238/1250) in the low-frequency group (risk difference, 2.2% [95% CI, -1.0% to 5.4%]; P = .15). CONCLUSIONS AND RELEVANCE: Among patients with stage II or III colorectal cancer, follow-up testing with computed tomography and carcinoembryonic antigen more frequently compared with less frequently did not result in a significant rate reduction in 5-year overall mortality or colorectal cancer-specific mortality. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00225641.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wille-Jørgensen P, Syk I, Smedh K, et al. Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. JAMA. 2018. PMID: 29800179. doi:10.1001/jama.2018.5623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。